Idorsia Ltd
IDRSF
Updated: 22/09/2026, 19:26:42
Established in 2017 and based in Allschwil, Switzerland, Idorsia Ltd operates as a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs. The company's diverse clinical development pipeline targets various therapeutic areas, including central nervous system (CNS), cardiovascular, and immunological disorders, alongside treatments for rare (orphan) diseases. Idorsia maintains a portfolio of strategic alliances: a joint development and commercialization agreement with Janssen Biotech Inc. for aprocitentan and its related products; a licensing deal with Mochida Pharmaceutical for the supply, co-development, and co-marketing of daridorexant; and a collaboration with Hoffman-La Roche Inc. to advance and market cancer immunotherapy compounds. Additionally, Idorsia is partnering with Antares Pharma, Inc. to create a self-administered drug device product for Selatogrel, and with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is currently undergoing Phase II clinical trials for epilepsy.
No summaries found.
- Share price
- $6.13
- Market cap
- $1.56B
- Exchange
- OTC
- Currency
- USD
- CEO
- Jean-Paul Clozel
- Employees
- 487
- IPO date
- 17/07/2017
- Beta
- 1.657
- Last dividend
- $0.00
- Day range
- $4.40 – $6.13
- 52-week range
- $3.82 – $8.19
- 1-day performance
- 0.00%
- 1-year performance
- 60.47%
- Current drawdown (1Y)
- -25.15%
- CIK
- N/A
- CUSIP
- N/A
- ISIN
- CH0363463438
- Created
- 07/12/2025, 04:40:35
- Last update
- 22/09/2026, 19:26:42
Track Idorsia Ltd with an AI analyst
See which prediction-market events move IDRSF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon
GlobeNewsWire • STOCK • 09/06/2026, 03:00:00
Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology
GlobeNewsWire • STOCK • 01/06/2026, 03:05:00
New analysis of Idorsia's aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
GlobeNewsWire • STOCK • 01/06/2026, 03:00:00
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
GlobeNewsWire • STOCK • 28/04/2026, 03:00:00
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders
GlobeNewsWire • STOCK • 10/04/2026, 03:00:00
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
GlobeNewsWire • STOCK • 09/04/2026, 03:00:00
Idorsia Ltd (IDRSF) Discusses Positive Phase II Results for Daridorexant in Pediatric Insomnia and Neurodevelopmental Disorders Transcript
Seeking Alpha • STOCK • 31/03/2026, 16:32:09
Idorsia announces the nomination of three candidates for election to the Board of Directors
GlobeNewsWire • STOCK • 24/03/2026, 03:00:00
Idorsia announces management change
GlobeNewsWire • STOCK • 16/03/2026, 03:00:00
Idorsia expands QUVIVIQ's global footprint through new partnership with Pharmalink
GlobeNewsWire • STOCK • 10/03/2026, 03:00:00
Idorsia Ltd (IDRSF) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 26/02/2026, 15:17:47
Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026
GlobeNewsWire • STOCK • 26/02/2026, 02:00:00